Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Caterpillar Inc (CAT) vs Enveric Biosciences Inc (ENVB) Price & Performance

Caterpillar IncTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Caterpillar Inc vs Enveric Biosciences Inc — how do they compare? Caterpillar Inc trades at $843.25 (market cap $385.01B), while Enveric Biosciences Inc trades at $1.45 (market cap $6.20M). The key difference: Caterpillar Inc is far larger — about 62098.4× Enveric Biosciences Inc's market cap, and Caterpillar Inc pays a 0.78% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

CATENVB
Market Cap
$385.01B$6.20M
Sector
IndustrialsHealth
52-Week High
$1.06K$17.40
52-Week Low
$407.79$1.27
Enterprise Value
$423.45B$1.30M
Dividend Yield
0.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Caterpillar Inc

Caterpillar (CAT) trades at $843.37, up 0.14% on the day, with strong year-to-date performance driven by robust earnings beats and AI data center demand. The stock shows a bearish technical signal but maintains solid fundamentals, including a net income margin of 14.51% and ROE of 56.99%. Recent news highlights growth from power and energy segments, with a dividend increase expected in June 2026.

Outlook remains positive due to earnings momentum and infrastructure tailwinds, though elevated valuation ratios like a P/E of 36.07 pose risks. Analyst consensus is bullish with a $1,010 price target, but investors should monitor economic cycles and competitive pressures that could impact future performance.

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Caterpillar Inc

Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.

Read more on CAT

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB